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Background: There are disparities in influenza and pneumococcal vaccination rates among elderly minority groups
and little guidance as to which intervention or combination of interventions to eliminate these disparities is likely
to be most cost-effective. Here, we evaluate the cost-effectiveness of four hypothetical vaccination programs
designed to eliminate disparities in elderly vaccination rates and differing in the number of interventions.
Methods: We developed a Markov model in which we assumed a healthcare system perspective, 10-year
vaccination program and lifetime time horizon. The cohort was the combined African-American and Hispanic
65 year-old birth cohort in the United States in 2009. We evaluated five different vaccination strategies: no
vaccination program and four vaccination programs that varied from “low intensity” to “very high intensity” based
on the number of interventions deployed in each program, their cumulative cost and their cumulative impact on
elderly minority influenza and pneumococcal vaccination rates.
Results: The very high intensity vaccination program ($24,479/quality-adjusted life year; QALY) was preferred at
willingness-to-pay-thresholds of $50,000 and $100,000/QALY and prevented 37,178 influenza cases, 342 influenza
deaths, 1,158 invasive pneumococcal disease (IPD) cases and 174 IPD deaths over the birth cohort’s lifetime. In
one-way sensitivity analyses, the very high intensity program only became cost-prohibitive (>$100,000/QALY) at
less likely values for the influenza vaccination rates achieved in year 10 of the high intensity (>73.5%) or very high
intensity (<76.8%) vaccination programs.
Conclusions: A practice-based vaccination program designed to eliminate disparities in elderly minority vaccination
rates and including four interventions would be cost-effective.
Keywords: Vaccination, Elderly, Disparities, Cost-effectivenessBackground
Influenza and invasive pneumococcal disease (IPD) are
vaccine-preventable infectious diseases that together ac-
count for >260,000 hospitalizations and >40,000 deaths
annually in the U.S. and disproportionately affect the
elderly [1-3].
In the elderly, influenza vaccination is recommended
annually and the pneumococcal polysaccharide vaccine
(PPSV) is recommended at age 65. Both vaccines are ef-
fective and widely available [4,5]. Yet, vaccination rates* Correspondence: michaelidis.constant@medstudent.pitt.edu
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article, unless otherwise stated.remain far below the Healthy People 2020 objective of
90%, and there are racial disparities in vaccination rates.
In the elderly, 67.7% of Caucasians, 56.1% of African-
Americans and 66.8% of Hispanics reported receiving in-
fluenza vaccination in 2010 and 63.5% of Caucasians,
46.2% of African-Americans and 39.0% of Hispanics
reported having ever received PPSV [6,7]. Given low vac-
cination rates seen in elderly minority and other popula-
tions, many interventions have been studied in an effort
to improve vaccination rates [8]. While many studies
suggest that single- and multi-component interventions
are effective, there are few cost-effectiveness evaluations
of these interventions and still fewer cost-effectiveness
evaluations of different combinations of interventionstral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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Figure 1 The Markov state transition diagram for each of five
different vaccination program strategies. During each one year
cycle, well patients could acquire influenza, invasive pneumococcal
disease or both and subsequently either recover, become disabled
or die. All patients ended each one year cycle in one of the
following three health states: well, disabled or dead. Patients in the
well and disabled states could also die based on all-cause and
disability-associated mortality. The only differences between the no
program and the four different vaccination program strategies are
the cost of the vaccination program and the probability of receiving
influenza and pneumococcal polysaccharide vaccination.
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First, practices motivated to adopt new strategies to in-
crease elderly minority vaccination rates have a menu of
effective interventions from which they may choose,
based on Task Force for Community Preventive Services
guidelines [8,10]. Second, while it is clear that multi-
component interventions are more effective than single-
component interventions, it is unclear if they are also
more cost-effective [8,9]. Thus, for practices seeking to
eliminate disparities in elderly minority vaccination
rates, there is little guidance as to which intervention or
combination of interventions is likely to be most cost-
effective.
Prior exploratory analyses have suggested that vaccin-
ation programs to eliminate disparities in elderly minor-
ity influenza and pneumococcal vaccination rates are
cost-effective when programs cost less than $9-11 per
targeted elder per year and result in minority vaccination
rates that match Caucasian vaccination rates [11,12].
Here, we extend these exploratory analyses by evaluating
the cost-effectiveness of four hypothetical vaccination
programs designed to eliminate racial disparities in eld-
erly influenza and pneumococcal vaccination in the out-
patient setting and differing primarily in “intensity” (i.e.,
the number of interventions included in each program).
Methods
Model structure
To evaluate the cost-effectiveness of different vaccination
programs to eliminate disparities in elderly influenza and
pneumococcal vaccination rates, we developed a Markov
model with a one year cycle length, 10-year vaccination
program and lifetime time horizon using TreeAge Pro
2009 software (Figure 1). In a Markov model, a simulated
patient cohort iteratively transitions between different
health states over time, incurring associated healthcare
costs and decrements to quality or quantity of life. We
assumed a healthcare system perspective and incorporated
direct medical and direct non-medical costs per published
guidelines [13]. Our cohort was the combined African-
American and Hispanic 65 year-old birth cohort in the
United States in 2009, with differences in influenza and
pneumococcal vaccination rates modeled based on
population-weighted averages.
We evaluated five different strategies: no vaccination
program and four vaccination programs that varied from
“low intensity” to “very high intensity” based on the num-
ber of interventions deployed in each program, their cu-
mulative cost and their cumulative impact on elderly
minority influenza and pneumococcal vaccination rates
(Figure 2). Each program incorporated a different number
of interventions to increase vaccination rates. Three of
these interventions (patient reminders, practice standing
orders and practice audit and feedback) were selected forinclusion because they are well-studied, effective and inex-
pensive [8,14,15]. One intervention (practice vaccination
champion) was selected for inclusion as a hypothetical so-
lution to loss of gains in vaccination rates that can occur
in later years of an initially high-performing vaccination
program due to patient and provider fatigue [16]. A vac-
cination champion is an individual in the practice who
sets vaccination targets, motivates staff and disseminates
best practices. We elected to combine interventions in a
step-wise fashion because we were primarily interested in
evaluating programs that included different numbers of
interventions.
In each strategy, we assumed that the cohort entered
the model in a “well” state and transitioned to illness
states based on probabilities of vaccination, influenza,
IPD, hospitalization, disability and death (Figure 1). Dur-
ing each one year cycle, well patients could acquire
influenza, invasive pneumococcal disease or both and
subsequently either recover, become disabled or die.
Patients in the well and disabled states could also die
based on all-cause and disability-associated mortality.
All patients ended each one year cycle in one of the fol-
lowing three health states: well, disabled or dead. Only
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Figure 2 Model assumptions for the five different vaccination program strategies.
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influenza-associated mortality or increased risk of IPD.
Given IPD’s severity, we assumed that all individuals
with IPD were hospitalized. In the absence of available
data, we employed a previously described approach and
used meningitis rates as a proxy for disability rates for
patients hospitalized with invasive pneumococcal dis-
eases and widely varied this parameter in sensitivity ana-
lyses [12]. Mortality due to other causes was modeled
based on 2009 U.S. life tables for the population-
weighted elderly minority cohort [17,18]. The only
differences among the five program strategies were the
cumulative intervention costs and the probability of re-
ceiving vaccines.
Vaccination program parameters
In the no program strategy, we assumed that 61% re-
ceived the influenza vaccination each year and 43%
received the PPSV in year 1 based on the population-
weighted average of elderly African-Americans and His-
panics reporting having received the influenza vaccin-
ation in 2010–2011 and having ever received PPSV in
2010, respectively (Figure 2) [6,7,18]. In the no program
strategy alone, we assumed that the entire cohort that
reported ever receiving PPSV would be vaccinated in
year 1 of the model and that there would be no add-
itional PPSV use in subsequent years. This assumption is
conservative (i.e. biased in favor of the no program strat-
egy) because it concentrates the benefits of vaccination
uptake among younger, healthier patients with more
quality-adjusted life years (QALYs) at risk.
In the low intensity program (patient reminders), we
assumed that the program cost $2.00 per targeted elder
per year, reflecting literature estimates for the costs of
autodialed reminders, and caused an 8% absolute in-
crease in influenza and pneumococcal vaccination rates
by program year 3, with gradual influenza vaccinationrate declines and PPSV rate flattening in program years
3–10 (Figure 2) [8,19]. Between years 3–10, we mod-
eled a 50% loss of the year 1–3 gains in influenza vac-
cination rates based on author estimates of program
fatigue and varied this parameter widely in sensitivity
analyses [16]. These vaccination rate trajectories are
conservative in that they assume that the 8% increases
in year 1 reported in the literature were not achieved
until program year 3 and vaccination rate declines oc-
curred in years 3–10 despite continued vaccination
program expenditures. We assumed identical vaccin-
ation rate trajectories for the medium and high inten-
sity programs, although with greater peak vaccination
rate gains by year 3 (Figure 2). The cost per targeted
elder per year of the autodialed reminders reflects the
sum of time, equipment and supply costs to develop
an autodialed vaccination reminder system in a clinic
setting [19].
In the medium intensity program (patient reminders
and standing orders), we assumed that a standing order
intervention added $5.62 in costs per targeted elder per
year, reflecting literature estimates for the nursing labor
costs associated with screening and identifying patients
eligible for vaccination, and caused a 16% absolute in-
crease in vaccination rates by program year 3 [8,20].
This increase in vaccination rates is based on a system-
atic review of multi-component interventions used to
increase vaccination rates that included patient re-
minders [8]. The cost per targeted elder per year of the
standing order intervention reflects the cost of nursing
time to screen and identify patients eligible for vaccin-
ation and evaluate the patient’s willingness to be vacci-
nated reported in a prior economic analysis of an
inpatient standing order intervention for pneumococcal
vaccination [20].
In the high intensity program (patient reminders,
standing orders and audit and feedback), we assumed
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costs per targeted elder per year and caused a 20% abso-
lute increase in vaccination rates by program year 3
[8,14]. Given the absence of published cost data on audit
and feedback interventions, we estimated costs based on
annual programming costs ($5,060) for the University of
Pittsburgh Medical Center electronic medical record
system for a network of clinics serving 30,000 patients in
which 8.5% of patients in these clinics are minority el-
ders and varied this estimate widely in sensitivity ana-
lyses. This approach assumes that audit and feedback
intervention costs primarily reflect costs of electronic
medical record programming to gather and deliver vac-
cination progress report cards to physicians. We conser-
vatively allocated costs of the audit and feedback
intervention only to minority elders in this clinic net-
work. Because the audit and feedback intervention was
added to a program already containing two other com-
ponent interventions, we conservatively used a lower-
bound literature estimate for incremental absolute gains
in the vaccination rate (4%) due to audit and feedback
interventions [8,14]. This absolute gain is materially
lower than median absolute gains in vaccination rates
associated with audit and feedback interventions for di-
chotomous outcomes reported in systematic reviews
(16-17%) to reflect concerns regarding the independence
of effects of multiple interventions on vaccination rates
[8,14]. We then widely varied the incremental absolute
gains in the vaccination rate gains associated with the
high intensity vaccination program in sensitivity analysis.
In the very high intensity program (patient reminders,
standing orders, audit and feedback and vaccination
champion), we assumed that a practice vaccination
champion would add $8.23 in costs per targeted elder
per year based on author estimates that a medical as-
sistant employed by a clinic in the network described
above would dedicate one hour per week to leading the
vaccination program at an hourly wage cost of $14.51
with an additional 20% in fringe benefits [21]. Again,
we allocated costs of the vaccination champion only to
minority elders in the clinic network described above
and not to all elders. Based on author estimates, we as-
sumed that the practice champion had no added effect
on vaccination rates in year 1–3 of the model but pre-
vented declines in influenza vaccination rates and
caused an annual 1.5% increase in PPSV rates in years
1–10 of the program. The vaccination rates achieved in
all four vaccination programs are reasonable in the
context of elderly minority vaccination rates that have
been achieved elsewhere for influenza (68-80%) and
PPSV (73-77%) [22]. Given uncertainty regarding the
incremental cost and effectiveness of a practice vaccin-
ation champion, we varied these parameters widely in
sensitivity analyses (Table 1).Vaccine effectiveness
For influenza, we assumed that vaccination reduced in-
fluenza risk only in the year of vaccination and that
there were no changes in vaccine effectiveness with age
(Table 1). For PPSV, we assumed that vaccination ef-
fectiveness was a function of baseline effectiveness, de-
clining effectiveness with time, pneumococcal serotype
coverage and the percentage immunocompromised
(Table 2). Due to the absence of available data, declines
in PPSV effectiveness with time were modeled based on
expert panel estimates and varied widely in sensitivity
analyses [36]. We assumed that PPSV was effective only
against IPD and not against non-invasive pneumococcal
pneumonia [5].
Influenza and IPD incidence
We assumed a 10% annual risk of influenza and a 4%
hospitalization risk in influenza (Table 1). We modeled
age-specific estimates of IPD incidence, disability and
mortality based on 2007–2008 data from the Centers for
Disease Control and Prevention’s (CDC) Active Bacterial
Core Surveillance network (Table 2). As IPD incidence
varies by race, we incorporated race-specific IPD esti-
mates. Elderly African-American IPD incidence was esti-
mated for each elderly age cohort by applying the
African-American proportion of all IPD cases against
the total IPD incidence rates in each age cohort. In the
absence of data, we estimated elderly Hispanic IPD inci-
dence based on relative IPD incidence in pediatric
African-American and Hispanic populations (1.22:1) and
relaxed this assumption in sensitivity analyses [37]. We
then calculated a population-weighted average IPD inci-
dence for the cohort based on the relative size of the
elderly African-American and Hispanic populations [18].
To account for reductions in IPD incidence rates due to
current PPSV use, we adjusted elderly minority IPD inci-
dence rates at the age-cohort level using prior estimates
of IPD incidence reductions due to PPSV [38]. This cor-
rection provides an estimate of IPD risk if PPSV did not
exist. In one-way and probabilistic sensitivity analyses,
IPD incidence, IPD disability, IPD mortality, vaccine
serotype coverage and percentage immunocompromised
were varied across triangular distributions, based on max-
imum variation reported by the CDC’s ABCs network
between 2003 and 2010 (Table 1).
Costs and effectiveness
We measured costs in 2011 U.S. dollars, inflating prior
costs using the U.S. Consumer Price Index. We modeled
costs of the following: vaccination interventions, vaccine
dose and administration, vaccine side effect treatment,
outpatient care, hospitalization and disability (Table 1).
Costs were drawn from the medical literature, with
hospitalization costs reflecting National Inpatient Survey
Table 1 Parameter values for base case and sensitivity analyses
Parameter range
Description Base Low High Distribution Source
Probabilities
Influenza and PPSVa vaccination Figure 2 −50% +50% Triangle [Figure 2]
Vaccination side effects (local reactions) 0.13 0.06 0.20 Beta [23]
Influenza
Annual risk 0.10 0.03 0.21 Beta [24]
Vaccine effectiveness 0.58 0.34 0.74 Beta [25]
Clinic visit, given influenza 0.62 0.52 0.72 Beta [26]
Hospitalization, given influenza 0.04 0.01 0.07 Beta [26]
Increased risk of IPDb given influenza 0.10 0.08 0.13 Beta [24]
Death given influenza hospitalization 0.23 0.18 0.28 Beta [1,2]
IPD
Incidence, disability, mortality Table 2 −20% +20% Triangular [3], Estimate
Immunocompromised in cohort (%) Table 2 −20% +20% Triangular [3], Estimate
Vaccine serotype coverage (%) Table 2 −20% +20% Triangular [3], Estimate
PPSV vaccine effectiveness (yr post-vaccination) Triangular [27]
Year 1 0.80 0.60 0.90
Year 5 0.58 0.31 0.80
Year 10 0.00 0.00 0.10
Excess mortality due to disability (per year) 0.1 0.0 1.0 Triangular [24]
Costs
Vaccination program, per targeted elder per year Figure 2 −50% +50% Triangular [Figure 2]
Influenza vaccine and administration $20.97 $13.11 $28.83 Gamma [28]
PPSV and administration $33.47 $16.74 $55.79 Gamma [24]
Vaccine side effect treatment $0.76 $0.68 $4.01 Gamma [28]
Influenza and IPD symptomatic treatment $5.00 $0.00 $10.00 Gamma [Estimate]
Influenza
Seeking clinic care $67.19 $56.62 $77.76 Gamma [28]
Clinic visit $158.72 $120.51 $196.92 Gamma [28]
Hospitalization without death $5,001 $4,714 $5,406 Gamma [28]
Hospitalization with death $10,244 $9,432 $11,173 Gamma [28]
IPD
Hospitalization without death $27,357 $25,224 $30,093 Gamma [24]
Hospitalization with death $37,688 $33,919 $41,458 Gamma [24]
Disability (annual) $12,683 $10,451 $14,914 Gamma [29]
Durations
Vaccine side effects (days) 3 1 8 Gamma [30]
Influenza, outpatient (days) 7 3 10 Gamma [31]
Influenza, prior to seeking inpatient care (days) 2 1 3 Gamma [Estimate]
Influenza, inpatient (days) 7 4 10 Gamma [1]
IPD inpatient (days) 12 9 15 Gamma [32]
Utilities
One year of healthy life for >65 yr old (QALY) Uniform [33,34]
65-70 years 0.76 0.71 0.81
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Table 1 Parameter values for base case and sensitivity analyses (Continued)
70-75 years 0.74 0.69 0.79
75-80 years 0.70 0.65 0.75
80-85 years 0.63 0.58 0.68
>85 years 0.51 0.46 0.56
Vaccine side effects 0.95 0.71 1.00 Uniform [28]
Influenza, outpatient 0.65 0.49 0.81 Uniform [28]
Influenza, inpatient 0.50 0.38 0.63 Uniform [28]
IPD, inpatient 0.20 0.15 0.25 Uniform [32]
IPD, disabled 0.40 0.20 0.60 Uniform [35], Estimate
aPneumococcal polysaccharide vaccine.
bInvasive pneumococcal disease.
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ing that QALYs were a function of the time spent in a
given health state multiplied by the utility value of that
health state. For patients with influenza requiring only
outpatient care, influenza requiring inpatient care and
invasive pneumococcal disease requiring inpatient care,
we multiplied the time spent in each health state (con-
verting days to years) by the utility value of that health
state after adjusting for baseline utility of one year of life
for the 65 year old birth cohort (Table 1). Utility values
ranged from 0 (death) to 1 (perfect health), were defined
by activity limitation and perceived health and were
based on data from the 1990 National Health Interview
survey [33]. All costs and utilities were discounted at
3% per year per the guidelines of the U.S. Panel on
Cost-Effectiveness in Health and Medicine [13].
Analyses
We performed a cost-effectiveness analysis to determine
the incremental cost-effectiveness ratio (ICER) of eachTable 2 Epidemiology of invasive pneumococcal disease (IPD
IPD cases per 100,000 per year in the general population (all races)
African-American population
Hispanic population
African-American, Hispanic weighted average
IPD outcomes per 100,000 per year in the general population (all races)
IPD meningitis
IPD death
Pneumococcal polysaccharide vaccine serotype coverage (all races)
Population immunocompromised (all races)
aABCs: Active Bacterial Core Surveillance (ABCs) network, 2007–2008.
bEstimates of race-level IPD incidence do not include corrections for prior vaccinatio
cBased on ABCs population level data on incidence of IPD in the African-American p
dBased on relative incidence of IPD in African-American and Hispanic pediatric pop
eBased on incidence of IPD in African-American and Hispanic elderly populations anvaccination program strategy. Although a $50,000/QALY
threshold is commonly used to define cost-effectiveness,
a $100,000/QALY threshold is also reasonable [39]. Thus,
we identified the programs that were preferred at both
willingness-to-pay thresholds. We then performed one-
way and probabilistic sensitivity analyses to evaluate the
robustness of the model to parameter variation, with re-
sults for the probabilistic sensitivity analysis displayed as a
net monetary benefit acceptability curve.
Results
Base case analysis
The low, medium, high and very high intensity vaccin-
ation program strategies – including all illness costs –
were progressively more costly and more effective
(Table 3). The ICERs of the low, high and very high in-
tensity programs were, respectively, $358, $9,397 and
$24,479/QALY. The ICER of the medium intensity pro-
gram was $11,040/QALY but this strategy was elimi-
nated from consideration because its ICER was higher) in the U.S. elderly population, 2007-2008
Age cohorts
65-69 70-79 ≥80 Source
25.9 33.9 60.1 [ABCsa]
41.6 54.5 96.4 [Estimatebc]
34.0 44.6 78.9 [Estimatebd]
38.2 50.0 88.6 [Estimatebe]
1.6 1.3 1.3 [ABCs]
2.9 3.9 11.9 [ABCs]
74.1% 65.8% 62.9% [ABCs]
13.1% 20.2% 23.8% [ABCs]
n status explained in the text.
opulation.
ulations [37].
d relative population sizes [18].
Table 3 Base case results
Vaccination program Cost Incr. cost Effectiveness Incr. eff. ICER
No program $698.00 9.3615
Low intensity $698.90 $0.90 9.3641 0.0025 $358
Medium intensity $727.00 $28.10 9.3666 0.0025 Extendeda
High intensity $734.80 $36.00 9.3679 0.0038 $9,397
Very high intensity $776.90 $42.00 9.3696 0.0017 $24,479
aExtended dominance: other more effective strategies have a lower ICER; per guidelines this strategy was eliminated [13].
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[13]. The very high intensity program ($24,479/QALY)
was preferred at willingness-to-pay-thresholds of both
$50,000 and $100,000/QALY. Over the lifetime of the
birth cohort, the very high intensity program would be
expected to prevent 37,178 influenza cases, 342 influ-
enza deaths, 1,158 IPD cases and 174 IPD deaths
(Table 4).
One-way sensitivity analysis
The ICER of the very high intensity program remained
< $50,000/QALY across all parameter ranges tested ex-
cept at less likely values for the PPSV or influenza vac-
cination rates achieved in the high or very high intensity
programs or for the cost of the very high intensity pro-
gram (Table 5). The ICER of the very high intensity
program remained below < $100,000/QALY across all
parameter ranges tested except when the peak influenza
vaccination rate achieved in the high and very high in-
tensity program was, respectively, >73.5% or <76.8%.
Probabilistic sensitivity analysis
Results from the probabilistic sensitivity analysis are
displayed in Figure 3 in the form of a net monetary
benefits acceptability curve showing the probability of
the five vaccination program strategies being cost-
effective versus the societal willingness-to-pay thresh-
old. Higher intensity vaccination program strategies
were preferred at higher willingness-to-pay thresholds.
The very high intensity program was most likely to be
cost-effective at willingness-to-pay thresholds of greater
than $21,000/QALY.Table 4 Estimated public health impact of elderly minority in
Influenza
Cases
Vaccination program Cases Prevented Deaths P
No program 457,743 4,211
Low intensity 445,909 11,834 4,102
Medium intensity 434,072 23,671 3,993
High intensity 428,152 29,591 3,939
Very high intensity 420,565 37,178 3,869
Analysis assumed a 65 year old minority birth cohort in the United States, 10 year vThe expected value of perfect information (EVPI), a
measure of decision uncertainty, was $24 and $27 per
person affected by the decision at thresholds of $50,000
and $100,000 per QALY gained respectively. Assuming
a minority elderly population affected by the decision
of 8 million over a 10 year time horizon, the population
EVPI is $192 to 216 million.20 The expected value of
partially perfect information, which estimates the contri-
bution of parameters to the EVPI, shows that uncertain-
ties regarding vaccination program costs and effectiveness
comprise >90% of the EVPI, due in part to the wide
ranges they were assigned. Thus, further research to re-
move uncertainty regarding disparity program effects
on vaccination rates and the costs of such programs
could be considered if research costs were less than $167
to 194 million.
Discussion
Employing conservative assumptions, we found that a
very high intensity program deployed to eliminate dis-
parities in influenza and PPSV vaccination rates in eld-
erly minorities in the United States would be cost-
effective ($24,479/QALY). Further, in one-way sensitivity
analyses, the very high intensity program only became
cost-prohibitive (>$100,000/QALY) at less likely values
for two parameters.
This study adds an important level of detail to our un-
derstanding of vaccination program cost-effectiveness by
showing that multi-component vaccination programs
designed specifically to eliminate disparities in vaccin-
ation rates are likely to be cost-effective [8,19,20,40].
This finding is in accordance with prior work suggestingfluenza and pneumococcal vaccination programs
Invasive pneumococcal disease
Deaths Cases Deaths
revented Cases Prevented Deaths Prevented
3,124 471
109 2,843 281 430 42
218 2,559 565 388 83
272 2,415 709 367 105
342 1,966 1,158 298 174
accination program and lifetime time horizon.
Table 5 Results of one-way sensitivity analyses
Parameter values
Parameter Base case ICER > $50,000/QALY ICER > $100,000/QALY
PPSVa vaccination rate, very high intensity program (yr 10) 78.0% <68.0% n/ab
Cost of very high intensity program (per elder per year) $17.84 >$23.65 n/ab
PPSV vaccination rate, high intensity program (yr 10) 63.0% >71.7% n/ab
Influenza vaccination rate, very high intensity program (yr 10) 81.0% <78.2% <76.8%
Influenza vaccination rate, high intensity program (yr 10) 71.0% >72.7% >73.5%
aPneumococcal polysaccharide vaccine.
bMaximum variation in these parameters did not cause ICER of preferred program to cross $100,000/QALY threshold.
Results presented only for those parameters, ordered from most to least impact, causing the incremental cost-effectiveness ratio (ICER) of the very high intensity
vaccination program to cross $50,000 and $100,000/QALY willingness-to-pay thresholds.
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pneumococcal vaccination rates would be cost-effective
if they eliminate disparities in elderly minority vaccin-
ation rates and cost < $9-11 per targeted elder per year
[11,12]. Here, we found that the ICER of the very high
intensity program ($24,479) was lower than the ICERs of
minority vaccination programs described previously
($45,000-$48,000/QALY) [11,12]. These differences are
likely due to the very high intensity program resulting in
more vaccinations than previous programs (influenza
and PPSV together v. either vaccination alone) [11,12].
This study has several strengths. First, we incorporated
conservative assumptions regarding the costs and effect-
iveness of the four vaccination programs, assuming that
costs were assigned to each targeted minority elder per
year regardless of prior PPSV vaccination status, that
single year gains in vaccination rates reported in the lit-
erature were only realized by the third year of the pro-
gram, and that gains in vaccination rate either stagnated0
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Figure 3 Probabilistic sensitivity analysis for the five different vaccina
monetary benefit acceptability curve.(PPSV) or were lost (influenza) in years 3–10 for all but
the very high intensity vaccination program. Second, we
made no assumptions regarding the potential for this
elderly minority vaccination program to also increase
vaccination rates in the elderly Caucasian population
seen in the same practices. Third, the results were ro-
bust to wide variation in parameter values, with the very
high intensity program not becoming cost-prohibitive (>
$100,000/QALY) except when less likely values were
tested in sensitivity analyses for the influenza vaccination
rate achieved in year 10 of either the high intensity or
the very high intensity vaccination program.
This study also has several limitations. First, the study
evaluated the cost-effectiveness of four practice-based vac-
cination programs designed to eliminate disparities in in-
fluenza and pneumococcal vaccination rates. In theory,
this modeling choice limits the generalizability of our find-
ings to those practices or practice networks that serve a
large population of minority elders, have disparities in0,000 $150,000 $200,000
 per QALY gained)
Very high intensity program
High intensity program
Medium intensity program
Low intensity program
No program
tion program strategies. Results are displayed in the form of a net
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http://www.biomedcentral.com/1471-2458/14/718vaccination rates and have not adopted the interventions
described above. In practice, however, this study is likely
generalizable to any practice with elderly influenza and
pneumococcal vaccination rates that are less than or equal
to the baseline elderly minority vaccination rates modeled
in this study. Second, in the absence of better data, we
modeled declines in PPSV vaccine effectiveness based on
expert panel estimates and costs of audit and feedback
and practice vaccination champion interventions based
on author estimates. When varied widely in sensitivity
analyses, however, these parameters did not have a
large impact on the ICER of the preferred vaccination
program. Third, our modeling approach does not capture
vaccination effects in decreasing disease transmission to
susceptible unvaccinated persons, as would a dynamic
transmission model. However, since our targeted group,
the elderly, is not the core group for transmission in these
illnesses (as children are), these transmission effects would
likely be minimal.Conclusions
This analysis suggests that a very high intensity vaccin-
ation program that included four interventions to elim-
inate disparities in elderly minority influenza and PPSV
vaccination rates would be cost-effective at both $50,000
and $100,000/QALY willingness-to-pay thresholds. A
vaccination program including these four interventions
should be considered for adoption in community-based
practices seeking to address disparities in elderly minor-
ity vaccination rates. Further research on the costs and
effectiveness of such programs may be warranted and
could be undertaken in the form of a large pragmatic
clinical trial that would likely be economically reason-
able to conduct given the value of the information gar-
nered from such a trial.
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